Prothena Corp Public (PRTA) Other Accumulated Expenses (2012 - 2026)
Prothena Corp Public's (PRTA) quarterly Other Accumulated Expenses came in at $10.5 million in Q1 2026, up 13.8% year-on-year from $9.2 million in Q1 2025, and down 10.92% quarter-over-quarter from $11.8 million in Q4 2025.
Prothena Corp Public (PRTA) Other Accumulated Expenses (2012 - 2026) Analysis & Trends
Prothena Corp Public's Other Accumulated Expenses history runs 15 years deep, the most recent figure standing at $10.5 million for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 13.8% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $10.5 million, a 13.8% increase from a year earlier, with the FY2025 full-year figure at $11.8 million, down 25.61% from the prior year.
- Other Accumulated Expenses eased to $10.5 million in Q1 2026 per PRTA's latest filing, from $11.8 million in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $15.8 million in Q4 2024 and bottomed at $5.0 million in Q1 2022.
- The 5-year median for Other Accumulated Expenses is $10.5 million (2026), against an average of $10.7 million.
- Across the five-year window, Other Accumulated Expenses jumped 78.73% in 2022 and plunged 42.61% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $12.2 million in 2022, then advanced by 28.71% to $15.7 million in 2023, then rose by 1.16% to $15.8 million in 2024, then declined by 25.61% to $11.8 million in 2025, then declined by 10.92% to $10.5 million in 2026.
- Per Business Quant, the three latest PRTA Other Accumulated Expenses figures stand at $10.5 million (Q1 2026), $11.8 million (Q4 2025), and $8.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Prothena Corp Public | 458.13 Mn | 128.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.50 Mn |
| Dec 31, 2025 | 11.79 Mn |
| Sep 30, 2025 | 8.21 Mn |
| Jun 30, 2025 | 6.40 Mn |
| Mar 31, 2025 | 9.23 Mn |
| Dec 31, 2024 | 15.84 Mn |
| Sep 30, 2024 | 14.31 Mn |
| Jun 30, 2024 | 10.93 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 15.66 Mn |
| Sep 30, 2023 | 13.78 Mn |
| Jun 30, 2023 | 10.22 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | 12.17 Mn |
| Sep 30, 2022 | 13.17 Mn |
| Jun 30, 2022 | 7.15 Mn |
| Mar 31, 2022 | 4.96 Mn |
| Dec 31, 2021 | 9.81 Mn |
| Sep 30, 2021 | 7.37 Mn |
| Jun 30, 2021 | 7.94 Mn |